ERBB2 and breast cancer: Disruption of IFN-1 signalling (via non-functional mutation in the IFN1I receptor) in tumours arising in HER2/neu transgenic mice deregulated a number of genes, including aldehyde dehydrogenase-1A1 (ALDH1A1), the marker of breast cancer stem cells.